Source: Health Products Regulatory Authority (IE) Revision Year: 2016 Publisher: Teva Pharma B.V., Swansweg 5, 2031GA, Haarlem, Netherlands
Zanaflex 2 mg Tablets.
| Pharmaceutical Form |
|---|
|
Tablet. White to off-white, biconvex, round, tablets, 6 mm in diameter, debossed “T2” on one side and score line on the other. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. |
Each tablet contains 2 mg of tizanidine (as hydrochloride).
Excipient(s) with known effect: Each tablet contains 57.910 mg of lactose, anhydrous.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Tizanidine |
Tizanidine is a centrally acting skeletal muscle relaxant. Polysynaptic signal transmission at spinal interneuron level, which is responsible for excessive muscle tone, is inhibited and muscle tone reduced. |
| List of Excipients |
|---|
|
Lactose, anhydrous |
Blister PVC/PVDC/Aluminium.
Blister packs of 15, 20, 30, 50, 100, 120 and clinical pack 500 (10x 50) tablets.
Not all pack-sizes may be marketed.
Teva Pharma B.V., Swansweg 5, 2031GA, Haarlem, Netherlands
PA0749/054/001
Date of first authorisation: 25th January 2008
Date of last renewal: 28th December 2010
| Drug | Countries | |
|---|---|---|
| ZANAFLEX | Ireland, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
